Design Makes a Difference: A Meta-Analysis of Antidepressant Response Rates in Placebo-Controlled Versus Comparator Trials in Late-Life Depression
The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
Objective Qualitative reviews of late-life antidepressant clinical trials suggest that antidepressant response rates in comparator trials are higher than antidepressant response rates in placebo-controlled trials. No quantitative review has been conducted to test this hypothesis.Methods A meta-analysis was conducted of all published articles in peer-reviewed journals from 1985 to the present to identify randomized clinical trials contrasting antidepressant pharmacotherapy to placebo or an active comparator in late-life depressed outpatients. Sixteen studies (nine comparator trials and seven placebo-controlled trials) were identified. Antidepressant response rates in both placebo-controlled and comparator trials were extracted and submitted for analysis using multilevel meta-analysis procedures.Results The authors found significant variability in antidepressant response rates beyond chance. This variability decreased by 27% when the authors included study type in the model. As expected, antidepressant response rates in comparator trials were significantly higher (60%) than antidepressant response rates in placebo-controlled trials (46%).Conclusion Antidepressant response rates are higher in comparator trials as compared to placebo-controlled trials. These findings have important implications for combined medication and psychotherapy trials that use placebo-controlled medication conditions because the response rates from these conditions are likely to be lower than those from unblinded conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, results of another meta-analysis comparing placebo-controlled vs. comparator trials in LLD suggest that these effects may underestimate those in clinical settings, when patient expectations of improvement may be higher303.”
From Psychobiological factors of resilience and depression in late life (2019) · cites this paper as [303]
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Multilevel analysis techniques and applications
Hox, J. J., Moerbeek, M., & van de Schoot, R. (2002) · Cited by 6,728
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Gill, J. (2005) · Encyclopedia of Social Measurement · doi:10.1016/b0-12-369398-5/00166-3 · Cited by 3,114
Multilevel Analysis: Techniques and Applications
Robinson, T. J. (2003) · Journal of the American Statistical Association · doi:10.1198/jasa.2003.s281 · Cited by 1,039
Best evidence synthesis: An intelligent alternative to meta-analysis
Slavin, R. E. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00097-a · Cited by 949
Neurobiological Mechanisms of the Placebo Effect
Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S., & Zubieta, J.-K. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3458-05.2005 · Cited by 777
Roberts, J. K. (2007) · The Blackwell Encyclopedia of Sociology · doi:10.1002/9781405165518.wbeosh029 · Cited by 579
Overt versus covert treatment for pain, anxiety, and Parkinson's disease
Colloca, L., Lopiano, L., Lanotte, M., & Benedetti, F. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00908-1 · Cited by 552
Haddock, C. K., Rindskopf, D. M., & Shadish, W. R. (1998) · Psychological Methods · doi:10.1037//1082-989x.3.3.339 · Cited by 338
Self-citation
Research works printed but not linked: 1
- Wilson, 2005, Antidepressants versus placebo for the depressed elderly [Systematic Review], Cochrane Database of Systematic Reviews, 4, 4
Cited by
Items 101–145 of 145
Vijapura, S., Laferton, J. A. C., Mintz, D. L., Kaptchuk, T. J., & Wolfe, D. J. (2015) · Academic Psychiatry · doi:10.1007/s40596-015-0470-2 · Cited by 9
“expectations [13–16], patient preferences [17, 18], and contact frequency [19] affect antidepressant outcomes.”
BackgroundGaudiano, B. A., Ellenberg, S., Schofield, C. A., & Rifkin, L. S. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15m01879 · Cited by 9
Dong, L., Xu, L., Li, Y., Lv, Y., Liu, H., Li, Y., Xu, F., Wu, J., Zheng, Q., & Li, L. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.103 · Cited by 8
Placebos in clinical trials: unravelling a complex phenomenon
Mestre, T., & Lang, A. E. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30349-0 · Cited by 8
Rutherford, B. R., Choi, J.-W., Slifstein, M., O'Boyle, K., Abi‐Dargham, A., Brown, P. J., Wall, M., Vanegas‐Arroyave, N., Sakhardande, J., Stern, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.066 · Cited by 7
“Late life depression (LLD) is a prevalent and disabling condition among older adults that is often recurrent, can become chronic, and is frequently non-responsive to antidepressant medication (Consensus Conference, 1992; Rothschild, 1996; Alexopoulos et al., 1996; Sneed et al., 2008).”
BackgroundSelf-citationRetractedTwenty years after ‘Listening to Prozac but hearing placebo’. Do we hear placebo even louder?
Oronowicz-Jaśkowiak, W., & Bąbel, P. (2019) · Health Psychology Report · doi:10.5114/hpr.2019.83383 · Cited by 7
“…fact that there is no possibility that they are in a group receiving a pure placebo instead of a medication, and (2) the subjects are aware of the fact that there is a possibility that they are receiving either a medication or a pure placebo was 60.00% and 46.00%, respectively (Sneed et al., 2008).”
InfluentialClinical trial methodology and drug‐placebo differences
Kirsch, I. (2015) · World Psychiatry · doi:10.1002/wps.20242 · Cited by 5
“Increasing expectancy of getting a drug rather than a placebo increases the response to the drug and the placebo (5-7).”
BackgroundInclusion/exclusion criteria in late life depression antidepressant efficacy trials
Zimmerman, M. A., Multach, M. D., Clark, H., Walsh, E. K., Rosenstein, L. K., & Gazarian, D. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4560 · Cited by 5
“For the purpose of this study we also examined reviews of the geriatric depression literature (Taylor and Doraiswamy, 2004; Nelson et al., 2008; Sneed et al., 2008; Tedeschini et al., 2011; Mulsant et al., 2014) and identified one study that had not been included in our prior examination of the inclusion and exclusion…”
MethodBalance and gait in older electroconvulsive therapy recipients: a pilot study
Plakiotis, C., Barson, Vengadasalam, Haines, T. P., & O’Connor, D. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s42628 · Cited by 5
“These rates are considerably higher than antidepressant response rates in late-life depression, which were reported in a recent meta-analysis to be as low as 46% in placebo-controlled trials and no more than 60% in comparator trials.(4) ECT remains the treatment of choice for patients whose physical health is signific…”
Late onset depression: A recent update
Mahapatra, A., Sharma, P., & Khandelwal, S. (2015) · Journal of Mental Health and Human Behaviour · doi:10.4103/0971-8990.164799 · Cited by 8
Andrade, C. (2008) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.43631 · Cited by 5
“Antidepressant efficacy in placebo-controlled studies In a meta-analysis of studies in geriatric depression, Sneed et al.[2] showed that the antidepressant response rates were lower in trials which compared antidepressant with placebo than in trials which compared two antidepressants.”
ResultA randomised cross-over study assessing the “blue pyjama syndrome” in major depressive episode
Delmas, H., Batail, J.-M. V., Falissard, B., Robert, G., Rangé, M., Brousse, S., Soulabaille, J., Drapier, D., & Naudet, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-02411-x · Cited by 4
Atypical Antipsychotic Medications in Alzheimer’s Disease: Effectiveness Versus Expectations
Schultz, S. K. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08040517 · Cited by 4
Pharmacological Treatment of Depression
Abou‐Saleh, M. T., & Katona, C. (2010) · Wiley eBooks · doi:10.1002/9780470669600.ch86 · Cited by 3
Patient Education in Psychopharmacology and the Risk of Nocebo-Related Treatment Inefficacy and Harm
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f12016 · Cited by 3
L'efficacité thérapeutique : objectivité curative et effet placebo
Boussageon, R. (2004) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 13
Colloca, L., Horin, A. P., & Finniss, D. G. (2016) · Wiley eBooks · doi:10.1002/9781118455968.ch9 · Cited by 3
Deardorff, W. J., & Grossberg, G. T. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-015-0140-y · Cited by 2
Wirken Antidepressiva eigentlich?
Bschor, T. (2013) · NeuroTransmitter · doi:10.1007/s15016-013-0399-1 · Cited by 2
Moving Forward in Clinical Trials for Late-Life Disorders
Schultz, S. K. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31815d2eeb · Cited by 2
Nitzan, U., Grossman‐Giron, A., Sedoff, O., Maoz, H., Arad, O., Tilbor, E., Dror, C., & Bitan, D. T. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06593-x · Cited by 1
“Additional studies indicate that antidepressant response is weaker in placebo-controlled trials than in comparative open-label trials in which patients know they are receiving one of two medications (Kim and Holloway 2003; Roose and Schatzberg 2005; Sneed et al. 2008; Rutherford et al. 2009).”
Placebo treatment in mild to moderate depression
Pittrof, R. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x561285 · Cited by 1
Are SSRI Antidepressants Little More than Active Placebo? A Critical Exploration.
Abi‐Jaoude, E. (2011) · Cited by 2
Depression in Clinical Practice
Rabbani, M. (1970) · Bangladesh Medical Journal · doi:10.3329/bmj.v40i1.9954 · Cited by 1
Brown, P. J. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.05.020 · Cited by 1
Anxiety as signal, symptom, and syndrome
Glick, R. A., & Roose, S. P. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.007
Self-citationAshirova, M. O. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
Schönknecht, P., Allgaier, A., Henkel, V., Hegerl, U., & Mergl, R. (2011) · Nervenheilkunde · doi:10.1055/s-0038-1628444
Clinical trials in late‐life mood disorders
Ghio, L., Natta, W. M., Vaggi, M., & Ferrannini, L. (2015) · Wiley eBooks · doi:10.1002/9781118323434.ch10
McCue, R. E., & Kelleher, M. (2017) · Wiley eBooks · doi:10.1002/9781119152606.ch12
Addressing High Placebo Response in Neuroscience Clinical Trials
Doros, G. D., Lim, P., & Liu, Y. (2018) · ICSA book series in statistics · doi:10.1007/978-981-10-7829-3_7
Niefarmakologiczne działanie leków stosowanych w psychiatrii
Sterna, W. (2018) · Via Medica Journals
Physical Exercise and Geriatric Depression: An Opinion
Machado, S. E. D. C., Monteiro, D., Moutão, J. M. R. P., Murillo‐Rodríguez, E., Yamamoto, T., Paes, F., Cid, L., & Lima, J. L. (2020) · Revista Psicologia e Saúde · doi:10.20435/pssa.v12i1.807
“115-126 higher response rate for placebo was predicted by the low severity of the disease at the start of the study (Stein, Baldwin, Dolberg, Despiegel, & Bandelow, 2006), and in clinical practice, patients with mild to moderate depression are likely to have a better placebo response in clinical trials (Sneed et al.,…”
BackgroundComments on Expectancy, Cognition, and Antidepressant Response in Late Life Depression
Nelson, J. C. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.12.003 · Cited by 1
(2008) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000342207.45816.86
Current awareness in human psychopharmacology
(2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.891
Current awareness in geriatric psychiatry
(2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1912
(2009) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283277013
Scientific Evidence Of Healing With Use Of Faith And Positive Language In Psychotherapy
Zahoor, R. (2021) · Journal of Science & Technology · doi:10.55662/jst.2021.2302
A model of placebo responses in antidepressant clinical trials
Zilcha‐Mano, S., & Rutherford, B. R. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197645444.003.0015
Self-citationSeo, Y. K., Choi, S.-Y., Choi, Y., Choi, S.-M., Kwon, O., Kim, H., & Jung, I. C. (2024) · Medicine · doi:10.1097/md.0000000000038208
“[54] Clinically, the placebo effect is pronounced in patients with mild to moderate depression, [55] and responses to placebo have been reported to persist over time.”
BackgroundChapter 61. Treatment During Late Life
Brewster, K., Rutherford, B. R., & Roose, S. P. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as61
Self-citation医薬品開発・医薬品適正使用への活用を目指したModel-based meta-analysisに関する研究
Kashihara, Y. (2020) · Kyushu University Institutional Repository (QIR) (Kyushu University) · doi:10.15017/4060101
Shen, X., Kong, J., & Shen, X. (2026) · ISPRS International Journal of Geo-Information · doi:10.3390/ijgi15070283
Metadata
- Authors
- Sneed, J. R., Rutherford, B. R., Rindskopf, D., Lane, D. T., Sackeim, H. A., & Roose, S. P.
- Affiliations
- New York State Psychiatric Institute (US)
- The Graduate Center, CUNY (US)
- Corresponding author
- Sneed, Joel R.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 16
- Issue
- 1
- Pages
- 65-73
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W1979782653
- Cited by
- 140
- References
- 43
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 3 · 2021: 2 · 2020: 10 · 2019: 7 · 2018: 7 · 2017: 10 · 2016: 10 · 2015: 11 · 2014: 5 · 2013: 14 · 2012: 7
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (T32MH020004, T32 MH 20004, K23 MH 70056-01A1, K23MH085236, T32MH015144)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- geriatric depression, antidepressant treatment, older adults, unblinding, trial design bias
- MeSH terms
- Age Factors, Aged, Antidepressive Agents, Depressive Disorder, Humans, Placebos, Research Design, Models, Statistical, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.